CV Therapeutics
Palo Alto, California, United States
About CV Therapeutics
CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Funding stage: M&A
- Last round: Undisclosed (Jan 1991)
- Website: cvt.com
Industries & Categories
Biotechnology, Health Care, Manufacturing, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cv-therapeutics-2549420 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.